Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
ASCO 2022
The 2022 meeting of the American Society of Clinical Oncology, June 3 to 7 in Chicago.
Pharma
ASCO: Enhertu could transform breast cancer with HER2-low show
Enhertu's results in HER2-low breast cancer are “phenomenally spectacular,” said Ken Takeshita, M.D., global head of R&D at Daiichi Sankyo.
Angus Liu
Jun 5, 2022 8:00am
AZ's Enhertu could up the pressure on Gilead's Trodelvy: experts
Jul 13, 2022 11:00am
'The Top Line': ASCO data, rising health tech stars and more
Jun 10, 2022 6:00am
Merck counts 80-plus possible oncology drug approvals by 2028
Jun 8, 2022 1:38pm
ASCO: Merck exec talks early days, new Keytruda data
Jun 6, 2022 10:25am
ASCO: Is that a bad sign in Clovis' Rubraca ovarian cancer data?
Jun 6, 2022 8:00am
